Successful Opening of Ductus Arteriosus with Milrinone in a Newborn with Tetralogy of Fallot and Pulmonary Atresia.
10.5385/jksn.2011.18.2.365
- Author:
Chong Bock WON
1
;
Min Young KIM
;
Duk Young CHOI
;
Hye Jung CHO
;
So Yeon SHIM
;
Dong Woo SON
Author Information
1. Department of Pediatrics, Graduate School of Medicine, Gachon University of Medicine and Science, Incheon, Korea. sondw@gilhospital.com
- Publication Type:Comparative Study ; Case Report
- Keywords:
Congenital heart disease;
Tetralogy of Fallot;
Pulmonary atresia;
Ductus arteriosus;
Milrinone;
Phosphodiesterase inhibitor;
Newborn
- MeSH:
Cyclic Nucleotide Phosphodiesterases, Type 3;
Ductus Arteriosus;
Ductus Arteriosus, Patent;
Heart Diseases;
Humans;
Infant, Newborn;
Milrinone;
Pulmonary Atresia;
Pulmonary Circulation;
Tetralogy of Fallot
- From:Journal of the Korean Society of Neonatology
2011;18(2):365-369
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tetralogy of Fallot (TOF) assumes its' most severe form when accompanied by pulmonary atresia (PA). Preserving the patent ductus arteriosus to maintain pulmonary blood flow is life-saving for patients with this congenital heart disease. Milrinone, a selective phosphodiesterase III inhibitor, is a potent vasodilator. Here, we report the successful use of milrinone for a newborn infant with TOF and PA for keeping the ductus arteriosus open and thereby maintaining pulmonary circulation. Milrinone is a useful drug because of its inotropic, lusitropic, and pulmonary vasodilating effects, in addition to its ability to keep the ductus arteriosus open and its relatively mild side-effects. Case series and comparative studies will be needed in the future to verify the effectiveness of this drug.
